Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a twelve month low of $0.01 and a twelve month high of $1.99. The firm has a market capitalization of $833,000.00, a P/E ratio of 0.00 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.